De-escalated administration of bone-targeted agents in patients with breast and prostate cancer—A survey of Canadian oncologists
Author:
Publisher
Elsevier BV
Subject
Oncology
Reference20 articles.
1. Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art;Clemons;Current Oncology,2012
2. Time to put an end to the one size fits all approach to bisphosphonate use in patients with metastatic breast cancer?;Kuchuk;Current Oncology,2012
3. Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists;Bouganim;Support Care Center,2011
4. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocal 19 Aredia Breast Cancer Study Group;Hortobagyi;New England Journal of Medicine,1996
5. Dose-response in the treatment of hypercalcemis of malignancy by a single infusion of the bisphosphonate AHPrBP;Thiebaud;Journal of Clinical Oncology,1988
Cited by 24 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Dynamic Contrast Enhanced MR Perfusion and Diffusion-Weighted Imaging of Marrow-Replacing Disorders of the Spine;Radiologic Clinics of North America;2024-03
2. Interval Comparison of Zoledronic Acid Treatment in Patients with Metastatic Bone Disease, Is 4-Weekly or 12-Weekly More Effective?: A Systematic Review and Meta-analysis;Eurasian Journal of Medicine and Oncology;2023
3. The Rethinking Clinical Trials (REaCT) Program. A Canadian-Led Pragmatic Trials Program: Strategies for Integrating Knowledge Users into Trial Design;Current Oncology;2021-10-04
4. Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer;Journal of Bone Oncology;2021-10
5. Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey;Supportive Care in Cancer;2021-05-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3